Actively Recruiting
Predictors of Aspirin Failure in Preeclampsia Prevention
Led by Rockefeller University · Updated on 2025-10-30
130
Participants Needed
1
Research Sites
185 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Hypertensive disorders of pregnancy (including preeclampsia) are among the leading causes of pregnancy complications and maternal deaths worldwide. They also increase the risks to the babies. Numerous interventions have been suggested in order to reduce the rate of preeclampsia. Low-dose aspirin is the most beneficial prophylactic approach in this regard. Nevertheless, aspirin failure is not uncommon. The genetic, laboratory, and clinical factors associated with low-dose aspirin failure in the prevention of preeclampsia are largely unknown. The presence of a genetic variant in PAR4 receptor expressed on platelets, is associated with increased platelet function and possibly with aspirin failure.
CONDITIONS
Official Title
Predictors of Aspirin Failure in Preeclampsia Prevention
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Women aged 18 to 45 years with a prior history of preeclampsia who received low-dose aspirin in a subsequent pregnancy
- Aspirin was taken at an 81 mg dose before 16 weeks of gestation with at least 80% self-reported compliance
- The subsequent pregnancy lasted beyond 20 weeks of gestation
- Willingness to avoid non-prescription NSAIDs for one week before platelet function tests
- Healthy controls aged 18 years or older with no specific inclusion criteria for SNP assay optimization
You will not qualify if you...
- Age under 18 years or over 45 years
- Any significant adverse reaction to aspirin in the past
- Known bleeding disorders from personal or family history
- History of kidney or liver problems
- Current pregnancy
- Current use of antithrombotic medications such as aspirin, clopidogrel, warfarin, or direct oral anticoagulants
- Chronic hypertension or use of antihypertensive drugs
- Diabetes mellitus
- Known current cancer
- History of hemorrhagic stroke
- Exclusion by investigator's discretion for medical, psychological, or other reasons
- Rockefeller students and employees in the Coller lab
- Healthy controls under 18 years of age or excluded by investigator's discretion
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Rockefeller University
New York, New York, United States, 10065
Actively Recruiting
Research Team
R
Recruitment Office
CONTACT
A
Amihai Rottenstreich, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
BASIC_SCIENCE
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here